### Edgar Filing: ROBIN HOWARD W - Form 4

ROBIN HO Form 4	WARD W										
November 0	03, 2017										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIO								OMMISSION	OMB	PROVAL 3235-0287	
washington, D.C. 20349 Number.										0	
(Print or Type	Responses)										
ſ			2. Issuer Name <b>and</b> Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
				Earliest Tr pay/Year) 017	ransaction			_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) President & CEO			
				ndment, Date Original hth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	Tabl	o I Non D	)orivotivo (	Soouri	tios A ca	Person	or Bonoficial	v Ownod	
1.Title of Security (Instr. 3)	2. Transaction Data (Month/Day/Year)		ed Date, if	a I - Non-Derivative Securities Acquired         3.       4. Securities Acquired         Transaction(A) or Disposed of (D)         Code       (Instr. 3, 4 and 5)         (Instr. 8)         (A)         or			quired of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Common Stock (1)	11/01/2017			Code V M	Amount 83,334	(D) A	Price \$ 11.34	(Instr. 3 and 4) 235,838	D		
Common Stock (1)	11/01/2017			S	83,334	D	\$ 23.57 (2)	152,504	D		
Common Stock								410	I	by spouse	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: ROBIN HOWARD W - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) Execution Date, if T any C		4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 11.34	11/01/2017		М		83,334	02/01/2014	01/31/2018	Common Stock	83,334

## **Reporting Owners**

Relationships **Reporting Owner Name / Address** Director 10% Owner Officer Other **ROBIN HOWARD W** C/O NEKTAR THERAPEUTICS Х President & CEO **455 MISSION BAY BOULEVARD SOUTH** SAN FRANCISCO, CA 94158 Signatures Mark A. Wilson, 11/03/2017 Attorney-in-Fact \*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin on March 9, 2017 for stock options scheduled to expire on January 31, 2018.

This transaction was executed in multiple trades at prices ranging from \$22.96 to \$24.20. The price reported above reflects the weighted (2) average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at

which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.